Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
Survey
We asked 250 pharma professionals, What do you see as the fastest growing type
of drug delivery form?

Extended release 37%
Injectables 24%
Orally disintegrating 21%
Inhalable 8%
Dermal 10%

Talk to us:
jupton@advanstar.com

Advertise with us:
wblow@advanstar.com

25 November, 2013
How Pro-Active is Your Anti-Bribery Strategy?
The pharmaceutical sector needs to shape up to deal with the big uptake in bribery and corruption enforcement actions — and not just in the USA, write Toby Duthie and David Lawler ...Read more
Clearing the Remaining Emerging Market Hurdles
Despite the long-held promise of the emerging markets, dominance in these territories has eluded Big Pharma. Hussain Mooraj addresses the key issues and offers a strategy for success ... Read more
Seeing Beyond the Big Data Backlash
Is ‘Big Data’ just a load of hype? The recent backlash suggests it might be. But Peter Houston looks beyond the buzzwords to reveal what companies should be focusing on ... Read more
What Does the UK’s ‘New’ PPRS Mean for the Future of Value-Based Pricing?
Leela Barham ponders the future of VBP in the light of a new PPRS deal between industry and the UK government ... Read more
Pfizer and GlaxoSmithKline Form Combination Cancer Trial Pact
Phase I/II study to evaluate treatment of patients with melanoma using Pfizer's palbociclib and GSK's trametinib ... Read more
Product Profile
Sciformix
Product labeling– Increasing efficiency, enhancing quality, and delivering compliance
Pharmaceutical product labeling is a highly regulated and complex process. A product label is very specific in its content, with respect to safety data, adverse effects and compliance to country specific regulations. Read more.
Also in this issue
US: Medicare Wasting ‘Billions of Dollars’, Says Study
Has Pharma Finally Figured Out Social Media?
Pharm Exec’s Orphan Drug Pipeline Picks